1,060 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Thoma Capital Management LLC

Thoma Capital Management LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,060 shares of the company's stock, valued at approximately $819,000. Eli Lilly and Company comprises about 0.6% of Thoma Capital Management LLC's holdings, making the stock its 25th largest holding.

A number of other institutional investors and hedge funds have also modified their holdings of the business. NorthCrest Asset Manangement LLC raised its stake in shares of Eli Lilly and Company by 164.8% during the fourth quarter. NorthCrest Asset Manangement LLC now owns 18,126 shares of the company's stock worth $13,993,000 after buying an additional 11,280 shares during the last quarter. Members Wealth LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $633,000. Tableaux LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $335,000. PKO Investment Management Joint Stock Co bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $5,790,000. Finally, Northstar Financial Companies Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $835,000. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on LLY shares. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective for the company. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Truist Financial raised their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Stock Performance

LLY stock traded down $6.63 during midday trading on Wednesday, reaching $718.59. 2,937,655 shares of the company were exchanged, compared to its average volume of 3,624,941. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The business has a 50-day moving average price of $782.03 and a two-hundred day moving average price of $801.29. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a market capitalization of $681.03 billion, a price-to-earnings ratio of 61.37, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.58 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.